Table 3.
Patient Disposition and Study Drug Tolerability
| Variable | No. of Patients (%) |
|---|---|
| No. of patients enrolled | 102 |
| No. of patients treated | 100 |
| No. of patients completing ≥6 cycles | 60 (60) |
| Median no. of cycles completed [range] | 6 [1-8] |
| Reasons for early termination* | |
| Total no. of AEs | 27 |
| Thrombocytopenia | 9 |
| Fatigue | 6 |
| Neutropenia | 4 |
| Infusion-related reaction | 1 |
| Nausea | 1 |
| Renal failure | 1 |
| Cough | 1 |
| Pulmonary alveolar hemorrhage | 1 |
| Decline in performance status | 1 |
| Increase in platelet count | 1 |
| Leukopenia | 1 |
| Disease progression | 10 |
| Patient preference for reason other than AE | 1 |
| Other† | 2 |
AE indicates adverse event.
*
Forty patients completed <6 treatment cycles.
†
Other reasons for early termination included referral for bone marrow transplantation in 1 patient and a treatment delay >4 weeks in 1 patient.